Pembrolizumab Shows Further Promise for Melanoma In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected. by Brad Jones Forward Look Tackling Drug Resistance Researchers are studing new ways to keep treatments working longer. by Stephen Ornes Survivor Profile Living in the Here and Now A metastatic melanoma survivor is hopeful but realistic as new treatments become available. by Jenny Song Forward Look Cancer Immunotherapies Continue to Make Headway Drugs that harness the power of the immune system gain new approvals. by Alexandra Goho Survivor Profile Knowing Her Options When Christina McEvoy was diagnosed with stage IV melanoma, she took the reins of her care, traveling more than 600 miles for treatment and returning home to help other melanoma survivors. by Melissa Davlin First Person Keeping Sight of Hope A survivor keeps an eye on what's ahead after a rare cancer diagnosis. by Sue Russell Cancer Talk August 10: The Week in Cancer News Organizations work to broaden eligibility for cancer clinical trials, and an article explores the limitations of personalized mouse models. by Kate Yandell Being Candid About Cancer As a father with an aggressive brain cancer, I’ve opted against elaborate metaphors and in favor of candid speech when talking about cancer with my children. by Adam Hayden Sowing Seeds of Health A program helps cancer survivors start gardens as a way to increase their vegetable consumption and physical activity. by Ashley P. Taylor August 3: The Week in Cancer News A study indicates that being diagnosed with cancer as a child could lead to financial problems later, and the Trump administration relaxes restrictions on short-term health insurance policies. by Kate Yandell More Posts